Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics, a biopharmaceutical company specialising in the discovery and development of pharmaceutical products and technologies for the management of cancer, has received FDA approval on investigational new drug (IND) application for its anticancer drug candidate LOR-253.
Subscribe to our email newsletter
Lorus claimed that the drug has shown selective and potent antitumor activity in preclinical investigations with a variety of human cancers, including colon cancer and non-small cell lung cancer, and has demonstrated an excellent therapeutic window due to its low toxicity.
LOR-253 is a small molecule that has been optimised to inhibit a novel cancer target Metal-Responsive Transcription Factor 1 (MTF-1).
Following the approval, Lorus is now planning to initiate a dose escalation Phase I trial with LOR-253 in advanced or metastatic solid tumors.
The trial is expected to investigate the safety profile, tolerability, and antitumor activity of LOR-253 in cancer patients, as well as pharmacokinetic and pharmacodynamic properties of LOR-253.
Lorus said that the Phase I trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York.